	US 12,263,203 B2
	BTNL9 and ERMAP as novel inhibitors of the immune system for immunotherapies
Xingxing Zang, New York, NY (US); and Kaya Ghosh, Bronx, NY (US)
Assigned to Albert Einstein College of Medicine, Bronx, NY (US)
Filed by Albert Einstein College of Medicine, Bronx, NY (US)
Filed on May 5, 2020, as Appl. No. 16/867,500.
Application 16/867,500 is a continuation of application No. 15/525,092, abandoned, previously published as PCT/US2015/060292, filed on Nov. 12, 2015.
Claims priority of provisional application 62/084,124, filed on Nov. 25, 2014.
Prior Publication US 2020/0338161 A1, Oct. 29, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 38/17 (2006.01); A61P 35/00 (2006.01); C07K 16/18 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); C07K 14/47 (2006.01)

CPC A61K 38/1709 (2013.01) [A61K 39/395 (2013.01); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); C07K 16/18 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C07K 14/47 (2013.01); C07K 2319/30 (2013.01)]

15 Claims

1. A method of treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of a polypeptide comprising an isolated plasma-soluble polypeptide comprising a soluble portion of short form BTNL2 having the amino acid sequence set forth in SEQ ID NO: 4 and excluding the amino acid sequence set forth in SEQ ID NO: 3, wherein the polypeptide treats the tumor.